title: The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3.
abstract: Soluble decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor superfamily, has recently been reported to increase osteoclast (OC) differentiation. Its impact on the skeleton was reinforced by a study on DcR3 transgenic mice showing a decreased bone mass through the elevation of OC number, providing some initial evidence of DcR3 involvement in bone diseases. In this study we show that malignant plasma cells and T lymphocytes from myeloma patients directly produce DcR3, and this molecule supports the elevated formation of OCs in both peripheral blood and bone marrow from the patients. We also show that serum DcR3 levels in myeloma patients are significantly higher compared to controls.
authors.affiliation: Department of Human Anatomy and Histology, University of Bari, Bari, Italy.
authors.forename: Giacomina
authors.initials: G
authors.lastname: Brunetti
authors.forename: Angela
authors.initials: A
authors.lastname: Oranger
authors.forename: Giorgio
authors.initials: G
authors.lastname: Mori
authors.forename: Matteo
authors.initials: M
authors.lastname: Centonze
authors.forename: Graziana
authors.initials: G
authors.lastname: Colaianni
authors.forename: Rita
authors.initials: R
authors.lastname: Rizzi
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Liso
authors.forename: Alberta
authors.initials: A
authors.lastname: Zallone
authors.forename: Maria
authors.initials: M
authors.lastname: Grano
authors.forename: Silvia
authors.initials: S
authors.lastname: Colucci
mesh_terms: D000368:Aged; D001773:Blood Cells / Q000378:metabolism; D001847:Bone Diseases / Q000097:blood / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D016022:Case-Control Studies; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D010010:Osteoclasts / Q000187:drug effects / Q000502:physiology*; D010950:Plasma Cells / Q000378:metabolism / Q000473:pathology; D053245:RANK Ligand / Q000378:metabolism; D053323:Receptors, Tumor Necrosis Factor, Member 6b / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology / Q000502:physiology*; D012995:Solubility; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D053245:RANK Ligand; D053323:Receptors, Tumor Necrosis Factor, Member 6b; C505688:TNFSF11 protein, human; D014409:Tumor Necrosis Factor-alpha